United Therapeutics’ DeciPHer-ILD Study: A Closer Look at PH-ILD Patient Registry

United Therapeutics Corp. ((UTHR)) announced an update on their ongoing clinical study.

United Therapeutics Corp. is currently recruiting for the DeciPHer-ILD study, a real-world patient registry focusing on Group 3 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD). The study aims to gather comprehensive data on patients with PH-ILD to better understand the condition and improve treatment strategies. This registry is significant as it could lead to enhanced patient outcomes and inform future therapeutic developments.

The study involves prospective assessments of patients, with a focus on those receiving the inhaled medication Tyvaso/Tyvaso DPI. The intervention is primarily observational, aiming to monitor patient progress and collect genomic and biomarker data to identify potential clinical response markers.

The study is observational, using a cohort model with a prospective time perspective. It is non-interventional, meaning no new treatments are being tested, but rather existing treatments are being observed for effectiveness and safety. The primary purpose is to gather data that could lead to improved treatment protocols.

The study began on April 12, 2024, with its primary completion and estimated overall completion dates yet to be determined. The most recent update was submitted on September 2, 2025, indicating ongoing recruitment and data collection efforts.

The implications for the market could be significant, as positive findings from this study might enhance United Therapeutics’ market position and investor confidence, particularly if the data supports the efficacy of Tyvaso/Tyvaso DPI. This could also impact competitors in the pulmonary hypertension treatment space, potentially shifting market dynamics.

The DeciPHer-ILD study is ongoing, with further details available on the ClinicalTrials portal.